News
Call for Proposals:
Kentucky Lung Cancer Research Program: Investigator-Initiated Research Program Overview
In 2000, the Kentucky General Assembly established the Lung Cancer Research Fund. This 20-year initiative serves as the incentive for collaborative efforts of the University of Kentucky and the University of Louisville to become nationally recognized as leaders in lung cancer epidemiology, diagnosis and treatment. A Governance Board, appointed by the Governor, administers the Kentucky Lung Cancer Research (KLCR) Program. The Board allocates research funds to the universities to accelerate the science associated with reducing morbidity and mortality from lung cancer.
KLCR Program provides grant support for:
- New researchers who demonstrate promise and who have a supportive environment for their work;
- Established and productive researchers who propose to apply their prior work to lung cancer research;
- Researchers with novel ideas who wish to test their ideas and develop pilot data for seeking larger awards from the National Institutes of Health (NIH) and other funding sources; and
- Collaborative research between investigators at the University of Kentucky and the University of Louisville.
Guidelines and Application
Please see the attached documents for details:
KLCR Cycle 11 Grant Application Guidelines
KLCR Cycle 11 Grant Application
Briefly, Cycle 11 proposals must satisfy each of the following criteria:
1) Each proposal must cover a lung cancer or tobacco use research topic that fits into one of the four research programs of the Markey Cancer Center. The four programs are:
Cancer Cell Biology and Signaling
Cancer Prevention and Control
Experimental Therapeutics
Redox Injury and Repair
2) Each proposal must be the result of collaboration between at least one basic or population science researcher and one clinical researcher.
3) Each proposal must clearly articulate plans to utilize at least two of the Markey Cancer Center shared resources listed below. Letters of Intent and the grant application must include a letter of support from the directors of the shared resources to be used.
Biospecimen
Biostatistics
Flow Cytometry
Informatics
Redox Chemistry and Biology
4) Each proposal must articulate plans to use human subjects and/or human tissue by the end of the two year funding period.
Applications that were not preceded by a Letter of Intent (including shared resource letters of support), those not meeting the four criteria described above and/or those that are incomplete will be administratively withdrawn without review.
Timeline
Release Date: November 7, 2011
Letter of Intent Date: December 14, 2011
Application Due Date: January 6, 2012
Peer Review Dates: January 18 – March 1, 2012
Governance Board Review: March 14 – April 30, 2012
Start Date: May 1, 2012
End Date: April 30, 2014
Questions about this opportunity should be directed to Nathan Vanderford, PhD, at nathan.vanderford@uky.edu.
__________________________________________________________________________________________
New Radiation Therapy Aimed at Lung Cancer
Please follow the link below to find out more information about Stereotactic Body Radiation Therapy. This type of therapy is relatively new and appears to rid patients with early-stage lung cancer cells better than conventional radiotherapy. It may also increase a lung cancer patient's life expectancy:
Stereotactic Body Radiation Therapy
________________________________________________________________________________________
Join Tobacco-free Take Action!
Please visit the link below to find out more about Tobacco-free Take Action, a team of employees and students committed to improving compliance with our tobacco-free policy:
________________________________________________________________________________________
Markey Menu: Nutrition for You
Hosted by Karina Christopher, Registered Dietitian at the UK Markey Cancer Center
This blog is focused on providing tips ranging from taste changes to cancer survivorship. Good nutrition and exercise are key to improving cancer treatment outcomes and survivorship. This blog is meant to help patients and caregivers with their nutrition
er before, during, and after cancer treatment.
http://ukhealthcare.uky.edu/forums/blogs/markeymenu/default.aspx
________________________________________________________________________________________
New Program Guides Cancer Patients
The University of Kentucky Markey Cancer Center is helping cancer patients and their families with the launch of the state's first American Cancer Society Patient Navigator Program, made possible with support from AstraZeneca.
After a diagnosis, patients can seek information on the following:
Transportation, lodging and campus navigation: Resources are available to aid with traveling and lodging through the Society's Road to Recovery® and Hope Lodge® programs.
Coping strategies: Emotional support is available through a wide variety of programs. Complementary therapies such as Jin Shin Jyutsu® are available to help relieve stress and worry in patients.
Appearance-related needs: Local resources for items to use to help cope with the effects of treatment. Guidance also available to the Society's Look Good Feel Better® program.
Financial assistance: Financial assistance may be available to patients that qualify for bill paying during treatment.
Information on cancer types and treatment options: Appropriate literature available on diagnosis, treatment, prevention and end of life care, as well as information on the Society's free clinical trials matching service.
_____________________________________________________________________________________
KLCR Cycle 10 Grant Award Recipients:
KLCR Cycle 10 Investigator-Initiated grants required investigators at the University of Louisville and the University of Kentucky to collaborate on projects that involve and engage the expertise at both institutions.
Special congratulations goes to the following collaborations:
Jason Chesney, M.D., Ph.D. (UofL) and Younsoo Bae, Ph.D. (UK):"Controlled Inhibition of the Glycolytic Pathway for Lung Cancer-Targeted Therapy"
Teresa W.M. Fan, Ph.D. (UofL) and Rolf Joseph Craven, Ph.D. (UK): "Stable isotope-derived metabolomics to elucidate the mechanism of a tumor-associated cytochrome in lung cancer growth and metabolism"
Ramesh C. Gupta, Ph.D. (UofL) and Vivek M. Rangnekar, Ph.D. (UK): "Activation of the Par-4 Extrinsic Pathway for Suppression of Lung Cancer"
Goetz Kloecker, M.D. (UofL), Jun Yan, M.D. (UofL) and Edward A. Hirschowitz, M.D. (UK), John R. Yannelli, Ph.D. (UK): "Combined Orally Administered Yeast-derived β-Glucan with 1650 Tumor Vaccine in the Treatment of NSCLC"
W. Glenn McGregor, M.D. (UofL) and Zhigang Wang, Ph.D. (UK): "Rev1 and Carcinogen-Induced Lung Cancer"
_______________________________________________________________________________________
Secondhand Smoke
Most people know that smoking tobacco is very risky for the smoker. But did you know that tobacco smoke is dangerous for nonsmokers, too?
Each year secondhand smoke causes about 46,000 deaths to nonsmokers from heart disease and 3,000 deaths from lung cancer alone.
Please follow this link to learn more about how you can protect yourself and others:
Or please call 1-800-333-8874.
__________________________________________________________________________________________
__________________________________________________________________________________________